

epkinly[®]
 epcoritamab-bysp
 SUBCUTANEOUS INJECTION 4mg/48mg

The power of EPKINLY makes sustained remission possible

Approved to treat adults with **diffuse large B-cell lymphoma (DLBCL)** that has returned or that didn't respond after 2 or more treatments

EPKINLY was studied in a clinical trial of 148 patients

- 61% (90 patients) achieved remission: complete remission in 38% (56 patients) and partial remission in 23% (34 patients)
- Of the 90 patients who achieved complete or partial remission, half were estimated to still respond to EPKINLY for at least 15.6 months

EPKINLY for the treatment of DLBCL is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death.
- **Infections and low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).



Actor portrayals.



What's inside

Key points about EPKINLY	3
Questions for your healthcare provider	4
How EPKINLY works	5
Results with EPKINLY	6
How EPKINLY is given	10
Important Safety Information	12
Resources and support	14
Tips for talking to your healthcare provider	16

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

Why EPKINLY might be right for you

EPKINLY is a treatment that:

- **Can help you achieve and sustain remission***
 - 61% (90 of 148 patients) achieved complete or partial remission (complete remission in 38% [56 patients], partial remission in 23% [34 patients])
 - Of the 90 patients who achieved complete or partial remission, half were estimated to still respond to EPKINLY for at least 15.6 months
- **May help you achieve results in as few as 4 weeks**
 - Median† of 1.4 months for patients in the study; time varied from 1 to 8.4 months
- **Is given as an injection at your oncologist's office**
- **Is not chemotherapy or stem cell therapy**

*EPKINLY for the treatment of DLBCL is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.

†The median is the number that is exactly in the middle of range seen in the study.

SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to the risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

Keeping track of your top questions

Below are some common questions that you may want to discuss with your healthcare provider. Use the lines below to make notes on the answers during your conversation.

How likely is it that EPKINLY will put my cancer into remission?

How quickly could I see results, and how long might they last?

What could my treatment experience be like with EPKINLY?

If you have additional questions that you'd like to ask, list them here:

Question: _____

Answer: _____

Question: _____

Answer: _____

Question: _____

Answer: _____

Scan the QR code or visit
EPKINLY.com/DLBCL for more information.






Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

epkinly[®]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

EPKINLY harnesses the power of your own immune system

EPKINLY is a bispecific antibody designed to target 2 types of cells in your body—T cells and B cells

 <p>A diagram showing a single T cell (teal) and a single B cell (pink) with small protrusions on their surfaces.</p>	 <p>A diagram showing a cluster of B cells (pink) and one T cell (teal) below them.</p>	 <p>A diagram showing a T cell (teal) and a B cell (pink) with EPKINLY antibodies (teal and pink) binding to their respective receptors.</p>
<h3>T Cells</h3> <p>T cells are immune cells that fight infections, as well as cancer cells.</p>	<h3>B Cells</h3> <p>B cells are another type of immune cell, and in DLBCL, some B cells can become cancerous and grow uncontrollably.</p>	<h3>How EPKINLY Works</h3> <p>EPKINLY works by attaching to both your T cells and B cells, binding them together so that the T cells can attack and destroy B cells.</p>

SELECT IMPORTANT SAFETY INFORMATION

Because EPKINLY works with your immune system, it **can cause serious side effects, including cytokine release syndrome (CRS), neurologic problems**, infections, and low blood cell counts.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).


epkinly[®]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg


Initial
Analysis
1 year

Long-Term
Analysis
3 years

Powerful results: EPKINLY helps you achieve and sustain remission

EPKINLY for the treatment of DLBCL was approved based on patient responses and how long those responses lasted. There is a study underway to confirm the clinical benefit of EPKINLY.

In the clinical study:



How long did remission last?

Of the 90 patients who achieved **complete or partial remission**, half were estimated to still be in remission for at least

15.6 months

Of the 56 patients who achieved **complete remission**,
the majority still had no signs of cancer

SELECT IMPORTANT SAFETY INFORMATION

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/48mg



Remission in as early as 1 month

~4
weeks

Some patients achieved results in as few as 4 weeks
(median* of 1.4 months; time varied from 1 to 8.4 months)

*The median is the number that is exactly in the middle of range seen in the study.

How was EPKINLY studied?

EPKINLY was studied in 148 patients with DLBCL who had 2 or more treatments and whose cancer returned or did not respond.

Half of the patients had tried at least 3 other treatments (number of treatments tried varied from 2 to 11), such as chemotherapy, immunotherapy (uses your body's immune system to help fight cancer), stem cell transplant, and CAR T therapy (chimeric antigen receptor T cell).

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/48mg

Initial
Analysis
1 year

Long-Term
Analysis
3 years

Long-term results

When was this analysis done?

An analysis was done at 3 years (37 months) to learn more about long-term remission in patients treated with EPKINLY. Half of the patients in this analysis were followed for more than 3 years, and the other half were followed for less. This is the median, or middle point.

Understanding the clinical trial: a timeline



Overall response rates in the long-term analysis

57%* (85 of 148 patients) achieved **complete or partial remission** (signs of cancer either disappeared or decreased)

- **41%** (60 of 148 patients) achieved **complete remission** (signs of cancer disappeared completely)
- **17%** (25 of 148 patients) achieved **partial remission** (signs of cancer decreased)

*1-year analysis.

†3-year analysis.

‡Numbers do not add up to 57% due to rounding.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

How long did remission last?

Of the 85 patients who achieved **complete or partial remission**, half were estimated to still be in remission for at least

20.8 months

Of the 60 patients who achieved **complete remission**, half were estimated to still be in remission for at least

36.1 months

No conclusions should be drawn about what these results may mean for you. Please talk with your healthcare provider about any questions you may have.

SELECT IMPORTANT SAFETY INFORMATION

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

Unlike an infusion that may take time to administer, EPKINLY is given as an injection

You can receive EPKINLY at your oncologist's office

EPKINLY Dosing Schedule:



Step-up dosing is designed to help you safely adjust to treatment due to the risk of CRS

During the first 2 weeks of treatment, you will receive smaller “step-up” doses than the doses you will receive in week 3 and for the rest of your treatment.

- Before and for 3 days after each dose of EPKINLY in your first 4 weeks of treatment, you will receive other medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS in later doses of EPKINLY
- Your healthcare provider will discuss with you the need to be hospitalized for 24 hours after your first full dose of EPKINLY (week 3/third dose) due to your risk of CRS and neurologic problems
- You may have side effects during treatment. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts. Your treatment may be temporarily or completely stopped if you develop certain side effects
- If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule

*Your healthcare provider will decide how long you will receive treatment.

CRS=cytokine release syndrome.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).


epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Staying on EPKINLY helps you stay in remission

- You will receive EPKINLY for as long as your healthcare provider finds it is working for you and any side effects you may experience are manageable
- Your treatment could be delayed or stopped if you have certain side effects

SELECT IMPORTANT SAFETY INFORMATION

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. **The most common severe abnormal laboratory test results** include decreased white blood cells, decreased red blood cells, and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).


epcoritamab-bysp[®]
SUBCUTANEOUS INJECTION 4mg/48mg

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose of EPKINLY will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to the risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Tell your healthcare provider or get medical help right away

if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache;

confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.
- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Please see additional Important Safety Information on page 13.
Please see [Medication Guide](#).


epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg


Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. **The most common severe abnormal laboratory test results** include decreased white blood cells, decreased red blood cells, and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on page 12. Please see [Medication Guide](#).



MyNavCare Patient Support[®] is here to support you



With MyNavCare, you can receive personalized support throughout your treatment journey with EPKINLY from a dedicated team that cares



A partner on your treatment journey with EPKINLY

Your healthcare provider is your main source for treatment information. With MyNavCare, you gain access to additional resources and medication information.

- Dedicated support throughout your treatment
- Information about treatment access and financial support*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way



Financial assistance for eligible patients

MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients*
- Independent patient assistant foundation information†
- Genmab Patient Assistance Program



Ongoing personalized support

Your **Patient Engagement Liaison**‡ provides ongoing support throughout treatment. They're dedicated to you, helping to:

- Provide general information about your condition
- Connect you to third-party organizations that may be able to help
- Offer resources for you and your Care Partners

*Based on eligibility requirements and Terms and Conditions. Federal health care program (FHCP) patients are not eligible for MyNavCare copay support.

†Eligibility criteria are determined by each independent third-party foundation. MyNavCare does not determine eligibility and cannot guarantee foundations will offer assistance.

‡MyNavCare Patient Engagement Liaisons are part of the MyNavCare Patient Support Program and do not provide medical advice or work under the direction of the prescribing healthcare providers. They are trained to direct patients to speak with their healthcare provider about any treatment-related questions.

Contact a MyNavCare Support Specialist by calling 1-866-NAV-CARI (1-866-628-2271), Monday-Friday, 8 AM – 8 PM ET. You can also scan the QR code or visit www.MyNavCare.com to learn more.



Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

epkinly[®]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Support for you and your Care Partner

Here are some organizations that can help Patients and Care Partners connect with others, and provide information and resources throughout treatment.



CancerCare
www.cancercares.org
800-813-HOPE (4673)



American Cancer Society
www.cancer.org
800-227-2345



Lymphoma Research Foundation
www.lymphoma.org
800-500-9976



Blood Cancer United
www.bloodcancerunited.org
800-955-4572



Family Reach
www.familyreach.org
857-233-2764

Information for Care Partners

As a Care Partner, you have become an integral part of your loved one's healthcare team.

Some responsibilities you may take on during your loved one's treatment:

- **Decision-making:** Researching clinical trials and treatment options, helping to consider treatment choices, and being an advocate for your loved one
- **Emotional:** Encouraging your loved one to share their feelings and helping them feel supported
- **Treatment support:** Helping watch for potential side effects, attending appointments, and ensuring they have what they need throughout their treatments
- **Logistical:** Scheduling and driving them to appointments, running errands, and assisting with daily needs

There are many available resources that may be helpful to patients, families, and Care Partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).



CONSIDERING EPKINLY

Talk to your healthcare provider to see if EPKINLY is right for you

If you are considering treatment with EPKINLY, this tool can help you prepare for your appointment.

My previous treatments

Use this chart to write notes about your previous treatments so you can discuss them with your healthcare provider.

Previous treatment	What was your experience with this treatment? (eg, how you responded, side effects, dosing, how it was given)

My current medications

When considering a new treatment, you may have questions about your current medications:

My treatment goals

Write down what's important to you as you consider your next treatment.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

Questions about EPKINLY

Use this chart to take notes when discussing EPKINLY with your healthcare provider.

EPKINLY	Notes
How it works	
Potential treatment benefits	
How it is given	
Potential treatment risks	



Patient/Care Partner tip: Consider asking your healthcare provider if you can record the conversation on your device, so you can reference it at a later time.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).



EPKINLY delivers powerful efficacy that can transform uncertainty into hope

EPKINLY was studied in a clinical trial of 148 patients

- 61% (90 patients) achieved remission: complete remission in 38% (56 patients) and partial remission in 23% (34 patients)
- Of the 90 patients who achieved complete or partial remission, half were estimated to still respond to EPKINLY for at least 15.6 months

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death.
- **Infections and low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 12-13. Please see [Medication Guide](#).

Scan the QR code or visit
[EPKINLY.com/DLBCL](https://epkinly.com/DLBCL) for more information.



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536. Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY and *MyNavCare Patient Support* are registered trademarks of Genmab A/S.
All other trademarks and registered trademarks are the property of their respective owners.
©2025 Genmab A/S and AbbVie. All rights reserved.
12/2025 COM-US-EPK-0002243

epkinly[®]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg